alpha-synuclein oligomer inhibitors (WaveBreak/Eisai)

N/A

Report date: 2025/01/26 16:49:37
NME

Base Information

Drug Namealpha-synuclein oligomer inhibitors (WaveBreak/Eisai)
Drug Alias Namealpha-synuclein inhibitors (WaveBreak/Eisai)WTX-A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSynuclein alpha inhibitors
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson DiseaseLewy Body Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWaveBreak Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWaveBreak Therapeutics LtdEisai Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseLewy Body Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A